A Study of Apabetalone in Subjects With Long -COVID

Clinical trial NCT06590324 · RECRUITING

Trial details

NCT number: NCT06590324
Sponsor: Resverlogix Corp
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Post-Acute COVID-19 Syndrome

Start date: 2025-04-15
Primary completion: 2025-12-30
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.